Vanda Pharmaceuticals (VNDA) Net Margin (2010 - 2026)
Vanda Pharmaceuticals recorded quarterly Net Margin of 93.82% in Q1 2026, up 61.99% quarter-over-quarter from 246.83% in Q4 2025, and down 3488.0% year-over-year from 2.77% in Q1 2025.
Vanda Pharmaceuticals' Net Margin history runs 17 years deep, the most recent figure standing at 93.82% for Q1 2026.
- In Q1 2026, Net Margin fell 3488.0% year-over-year to 93.82%; the TTM figure through Mar 2026 stood at 109.99% (down 8802.0% YoY), while the FY2025 annual figure was 102.02%, down 9251.0% from the prior year.
- Net Margin came in at 93.82% for Q1 2026 at Vanda Pharmaceuticals, up from 246.83% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 10.64% in Q4 2022 to a low of 246.83% in Q4 2025.
- A 5-year average of 30.42% and a median of 8.95% in 2024 frame the typical range for Net Margin.
- Across the five-year window, Net Margin soared 1585 bps in 2023 and slumped 23767 bps in 2025, its largest moves.
- Vanda Pharmaceuticals' Net Margin stood at 10.64% in 2022, then slumped by 150 bps to 5.28% in 2023, then tumbled by 74 bps to 9.17% in 2024, then slumped by 2592 bps to 246.83% in 2025, then surged by 62 bps to 93.82% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 93.82%, 246.83%, and 40.15% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.65% |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | -93.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -93.82% |
| Dec 31, 2025 | -246.83% |
| Sep 30, 2025 | -40.15% |
| Jun 30, 2025 | -51.70% |
| Mar 31, 2025 | -58.94% |
| Dec 31, 2024 | -9.17% |
| Sep 30, 2024 | -11.21% |
| Jun 30, 2024 | -8.95% |
| Mar 31, 2024 | -8.77% |
| Dec 31, 2023 | -5.28% |
| Sep 30, 2023 | 0.35% |
| Jun 30, 2023 | 3.24% |
| Mar 31, 2023 | 5.16% |
| Dec 31, 2022 | 10.64% |
| Sep 30, 2022 | 4.99% |
| Jun 30, 2022 | 4.02% |
| Mar 31, 2022 | -10.68% |
| Dec 31, 2021 | 10.41% |
| Sep 30, 2021 | 11.09% |
| Jun 30, 2021 | 14.22% |
| Mar 31, 2021 | 13.80% |
| Dec 31, 2020 | 12.13% |
| Sep 30, 2020 | 9.86% |
| Jun 30, 2020 | 13.97% |
| Mar 31, 2020 | 0.84% |
| Dec 31, 2019 | 6.95% |
| Sep 30, 2019 | 168.82% |
| Jun 30, 2019 | 19.52% |
| Mar 31, 2019 | -1.28% |
| Dec 31, 2018 | 19.57% |
| Sep 30, 2018 | 14.58% |
| Jun 30, 2018 | 9.74% |
| Mar 31, 2018 | 7.03% |
| Dec 31, 2017 | -4.15% |
| Sep 30, 2017 | -11.01% |
| Jun 30, 2017 | -3.65% |
| Mar 31, 2017 | -20.43% |
| Dec 31, 2016 | -1.31% |
| Sep 30, 2016 | -1.12% |
| Jun 30, 2016 | -12.82% |
| Mar 31, 2016 | -37.15% |
| Dec 31, 2015 | -46.76% |
| Sep 30, 2015 | -33.66% |
| Jun 30, 2015 | -19.79% |
| Mar 31, 2015 | -46.47% |
| Dec 31, 2014 | 453.44% |
| Sep 30, 2014 | -9.80% |
| Jun 30, 2014 | -198.63% |
| Mar 31, 2014 | -290.20% |
| Dec 31, 2013 | -86.79% |
| Sep 30, 2013 | -61.78% |
| Jun 30, 2013 | -40.67% |
| Mar 31, 2013 | -56.01% |
| Dec 31, 2012 | 256.84% |
| Sep 30, 2012 | -64.26% |
| Jun 30, 2012 | -95.57% |
| Mar 31, 2012 | -97.80% |
| Dec 31, 2011 | -65.99% |
| Sep 30, 2011 | -38.57% |
| Jun 30, 2011 | -18.05% |
| Mar 31, 2011 | 1.81% |
| Dec 31, 2010 | -58.13% |
| Sep 30, 2010 | 43.94% |
| Jun 30, 2010 | 83.01% |